TheStreet's Jim Cramer says investors need to see money come back to high-growth names, which have seen a shrinking price-to-earnings multiple. Celgene has been in a decline but the company could have $15-$16 earnings power in a couple of years, says Cramer, and it is cheaper than Merck and Pfizer. Cramer is also watching Salesforce.com, which has seen a shrinking multiple since it reported a great quarter. If Celgene and Salesforce turn around, money will come back to high-growth from value names.

At the time of publication, Cramer was long ___.

More from Video

The CEO of Wall Street Disruptor Symphony Reacts to Tuesday's Market Declines

The CEO of Wall Street Disruptor Symphony Reacts to Tuesday's Market Declines

60 Seconds: What is the Yield Curve and Why is it Screaming Recession?

60 Seconds: What is the Yield Curve and Why is it Screaming Recession?

Coke Has Figured Out How to Stay Relevant (Watch)

Coke Has Figured Out How to Stay Relevant (Watch)

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Video: Jim Cramer on Rising Interest Rates, Trade Worries & Caterpillar

Video: Jim Cramer on Rising Interest Rates, Trade Worries & Caterpillar